# Abivax S.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Abivax S.A.). ## Overview Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases. It is based in France and the United States and centers on advancing its lead drug candidate, obefazimod (ABX464), through late-stage clinical development. ## Products & services • Obefazimod (ABX464) for chronic inflammatory diseases • Clinical development of immune-modulating therapeutics • Phase 3 development program in ulcerative colitis • Preclinical and clinical-stage pipeline research - **Lead drug candidate** (100%) — Obefazimod and related development programs for inflammatory diseases. - Obefazimod (ABX464) for chronic inflammatory diseases - Clinical development of immune-modulating therapeutics - Phase 3 development program in ulcerative colitis - Preclinical and clinical-stage pipeline research ## Customers Abivax does not sell commercial products broadly; its direct business counterparties are primarily clinical trial sites, contract research organizations, regulators, and development partners involved in advancing its drug candidates. The ultimate end customers, if approved, are patients with chronic inflammatory diseases such as ulcerative colitis. In practice, the company’s value proposition is tied to demonstrating clinical efficacy and safety that could support future pharmaceutical adoption. - **Clinical development partners** (primary) — CROs, investigators, labs, and manufacturers that execute the development program. - **Regulatory stakeholders** (primary) — Health authorities and ethics committees that assess trial data and approvals. - **Patients with inflammatory disease** (primary) — The intended end users of obefazimod if the therapy reaches commercialization. - **Future healthcare payors** (emerging) — Insurers and public health systems that would reimburse treatment use after approval. - Clinical investigators and trial sites running the studies - Contract research and manufacturing partners supporting development - Regulators and ethics committees reviewing the clinical program - Patients with chronic inflammatory diseases such as ulcerative colitis - Potential future payors and healthcare systems if approved ## Geography Abivax is headquartered in France with a U.S. presence and reports activity tied to both Europe and the United States. Its development operations are therefore exposed to transatlantic clinical, regulatory, and capital market requirements rather than a single national market. The company’s quoted listings in Paris and on Nasdaq also reflect that dual geographic footprint. - Headquartered in Paris, France - Operates with a U.S. presence for clinical and capital market access - Development activity spans Europe and the United States - Listed on Euronext Paris and Nasdaq - Regulatory exposure follows both EU and U.S. pathways ## Strategy Abivax’s strategy is centered on advancing obefazimod through late-stage clinical development in ulcerative colitis and building evidence for immune-modulating therapies in chronic inflammatory disease. The company’s competitive position depends on translating clinical data into regulatory progress and, ultimately, a differentiated therapeutic profile. It also maintains the financing and corporate infrastructure needed for a long development cycle. - **Complete late-stage clinical development** (short-term) — Clinical readouts are the main value driver for a single-asset biotech company. - **Strengthen regulatory positioning** (short-term) — Approval pathways depend on robust efficacy, safety, and quality data. - **Preserve long-duration development capacity** (medium-term) — Biotech development requires funding and operating flexibility over multiple years. - Advance obefazimod through Phase 3 development - Build clinical evidence in ulcerative colitis - Extend platform science to chronic inflammatory diseases - Maintain access to public and equity financing - Support regulatory and clinical execution across regions ## Risks Abivax faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delays, and uncertainty around whether trial data will be strong enough for approval. Because its value is concentrated in a small number of programs, any setback in obefazimod or its inflammatory disease pipeline could materially affect the business. - **Clinical development failure** [critical] — The company depends on obefazimod progressing successfully through late-stage trials. - **Regulatory and approval risk** [high] — Regulators may request further data on efficacy, safety, or manufacturing quality. - **Financing and dilution risk** [high] — Clinical-stage companies often require repeated external capital before commercialization. - **Pipeline concentration** [high] — The company’s value is concentrated in a limited number of programs and indications. - Clinical trial results may not show sufficient efficacy or safety - Regulatory review could require additional studies or delay approval - Single-asset concentration increases dependence on obefazimod - Biotech development requires ongoing access to external funding - Adverse events or CMC issues can disrupt development timelines ## Accounting As a clinical-stage biotech, Abivax’s reported numbers are shaped by judgments around research and development spending, fair value measurements, and financing instruments rather than product revenue. The reports also highlight estimation uncertainty, liability derecognition timing, and the accounting treatment of borrowings, convertible instruments, and derivative features, all of which can affect the balance sheet and reported income. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Fair value measurement of financing instruments** — Can create non-cash volatility in income and liabilities - **Estimation uncertainty and judgments** — Can materially affect reported assets, liabilities, and expense timing - **Liability derecognition under IFRS 9** — Affects timing of liability removal and related financial statement presentation - R&D expense recognition drives the reported loss profile - Fair value estimates affect derivatives and financing instruments - Convertible notes and borrowings influence liabilities and finance costs - Judgment and estimation uncertainty are material in a biotech setting - IFRS 9 policy changes affect when liabilities are derecognized --- *Last updated: 2026-09-28T11:57:35.230901+00:00*